ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pairwise and Tropic Biosciences Announce Licensing Deal to Utilize Base Editing Technology to Drive Innovation in Bananas and Coffee

Pairwise, a U.S. mission-driven food tech company that uses gene editing to develop new varieties of fruits and vegetables, and Tropic Biosciences (Tropic), a U.K. agricultural technology company focused on tropical crops, announced a deal that will grant access to base editing technologies in order to extend its game-changing potential to critically important crops with major global economic impact.

Base editing allows for precise and targeted changes to DNA and will enable Tropic to further accelerate plant breeding innovation in coffee and banana crops. Pairwise initially licensed base editing technologies from Harvard University, and has proven out the use of that technology across its portfolio, demonstrating the ability to transform and edit over 11 crops to date. The precision that base editing affords has allowed Pairwise to access traits that were not feasible with earlier editing technologies, unlocking a greater scope of natural variation found in these crops. This license agreement further extends the use of this technology to important tropical crops.

“As a mission-driven company, we believe it is imperative to forge alliances with other visionary companies who can extend our mission of building a healthier world,” said Ian Miller, Chief Development Officer of Pairwise. “This deal with Tropic Biosciences is an important step in the development of new varieties of tropical crops upon which billions of consumers and tens of millions of smallholder farmers rely, and further demonstrates the ability of our platform technologies to solve problems across the plant-based economy.”

“Gene editing is a once-in-a-generation type of innovation, and adding this powerful suite of base editing tools to the Tropic Biosciences toolbox will further support our efforts to address pressing challenges in bananas and coffee.” said Gilad Gershon, Chief Executive Officer of Tropic. “The deal with Pairwise is exciting, and will support our mission of bringing important innovation to regions and growers who would greatly benefit from better cultivation efficiencies, and improved sustainable environmental practices.”

Today, Tropic works on the big-acre, tropical crops of bananas, coffee, and rice, using its GEiGS® technology and other advanced breeding techniques. Given the dual pressures of climate change and disease, Tropic’s work could have a profound impact on the 25 million-plus coffee and banana growers worldwide, and the 400 million people who consume bananas and one billion people globally who consume over 1 million kilograms of coffee per year.

Pairwise is currently developing new types of leafy greens, berries, and cherries for consumers in the North American marketplace. Additionally, Pairwise has a $100 million, five-year collaboration with Bayer Crop Science to advance gene editing tools in row crops. In February 2021, Pairwise raised $90 million in a successful series B funding round, bringing total fundraising to $115 million when combined with the series A funding round. In three years, the company has grown to over 130 employees with additional anticipated growth in 2022.

About Pairwise

Driven by the belief that healthy food should be consistently fresh, delicious, and convenient, Pairwise brings together leaders in agriculture, technology, and consumer foods to harness the transformative potential of new genomics technologies to create innovative new products. Pairwise is working to develop new varieties of crops, and to partner with organizations that seek to drive innovation across the plant-based economy. The company was founded by Chief Executive Officer Tom Adams and Chief Business Officer Haven Baker, with scientific co-founders J. Keith Joung, Professor of Pathology at Harvard Medical School, David Liu, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; and Feng Zhang, McGovern Investigator and a professor at MIT. For more information, visit http://www.pairwise.com/.

About Tropic Biosciences

Tropic Biosciences is one of the world’s leading agricultural gene-editing companies. Its team of over 120 professionals focuses on utilizing a unique suite of genetic technologies (e.g. CRISPR, GEiGS®) in addressing some of the most critical agricultural and environmental challenges in the massive coffee, banana and rice industries. For more information, visit http://www.tropicbioscience.com/.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.